Condition
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Recruiting4
Unknown1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06388421RecruitingPrimary
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06512935Not ApplicableRecruiting
Ventilator Pressure and Optimization of Compliance and Hemodynamics
NCT04808596Recruiting
Pulmonary Hypertension Biorepository and Registry
NCT04467333RecruitingPrimary
Giessen Pulmonary Hypertension in Lung Cancer Registry
NCT04499196UnknownPrimary
Glucocorticoids and Pulmonary Hypertension
Showing all 5 trials